From: Adherence to metformin in adults with type 2 diabetes: a combined method approach
Variable | Total |
---|---|
N = 121 | |
Duration of diabetes: [mean years ± SD] | 14.7 ± 6.4 |
Age: [mean years ± SD] |  ± 9.7 |
 18–65 years [n (%)] | 45 (37.2) |
 > 65 years [n (%)] | 76 (62.8) |
Sex | Â |
 Female [n (%)] | 38 (31.4) |
 Male [n (%)] | 83 (68.6) |
BMI: [mean kg/m2 ± SD] | 34.1 ± 7.5 |
Lean Body Weight: (mean kg ± SD) | 61.7 ± 11.8 |
Other medical condition | Â |
 No [n (%)] | 2 (1.7) |
 Yes [n (%)] | 119 (98.3) |
Number of other medical conditions: [median [IQR]] | 7 [3–11] |
Number of antidiabetic medicines (oral or injection) prescribed: [median [IQR]] | 3 [3, 4] |
 1 [n (%)] | 2 (1.7) |
 2 [n (%)] | 22 (18.2) |
 3 [n (%)] | 62 (51.2) |
 > 3 [n (%)] | 35 (28.9) |
Number of all medicines prescribed: [mean ± SD] | 10.8 ± 4.4 |
 ≤ 5 [n (%)] | 8 (6.6) |
 6–9 [n (%)] | 44 (36.4) |
 ≥ 10 [n (%)] | 69 (57.0) |
HbA1c: [mean mmol/mol ± SD] | 67.9 ± 17.9 |
Random glucose level: [mean mmol/L ± SD] | 9.9 ± 4.1 |
Metformin concentration in plasma: [median μg/mL [IQR]] | 1.6 [1.2–2.2] |
Serum creatinine level: [mean μmol/L ± SD] | 91.0 ± 32.4 |
Haematocrit level: [mean % ± SD] | 39.1 ± 5.2 |